Published • loading... • Updated
AC-201, an TYK2/JAK1 Inhibitor, Hits PASI-75 at Week 12 in Psoriasis Phase 2 Trial
- Accropeutics announced positive Phase 2 trial results of AC-201, an oral TYK2/JAK1 inhibitor, for moderate-to-severe plaque psoriasis on May 20, 2025.
- The randomized, double-blind, placebo-controlled trial involved 145 Chinese patients and aimed to evaluate PASI-75 and sPGA-0/1 endpoints at Week 12.
- All three dosing groups of AC-201 achieved primary and key secondary endpoints with no serious adverse events or discontinuations reported.
- PASI-75 response rates reached up to 71.4% sPGA-0/1 at 50mg BID , while placebo rates were 8.1% for PASI-75 and 5.4% for sPGA-0/1.
- The positive efficacy and safety outcomes from the Phase 2 trial of AC-201 justify progressing the drug to Phase 3 studies and highlight its promise for treating psoriasis as well as other immune-mediated inflammatory conditions.
Insights by Ground AI
53 Articles
53 Articles
WDEL 101.7FM+49 Reposted by 49 other sources
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuationEfficacy and safety findings…
·Wilmington, United States
Read Full Article
Accropeutics’ TYK2/JAK1 inhibitor meets endpoints in Phase II psoriasis trial
Accropeutics said the Phase II trial of AC-201 will support the drugs progression to a Phase III trial in plaque psoriasis.The post Accropeutics’ TYK2/JAK1 inhibitor meets endpoints in Phase II psoriasis trial appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources53
Leaning Left4Leaning Right6Center28Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
C 74%
R 16%
Factuality
To view factuality data please Upgrade to Premium